Med Ad News announces the 28th Annual Manny Awards nominees; FCB Health CEO/President Dana Maiman named ad industry Person of the Year.
Eli Lilly and Co.’s combination of its experimental breast cancer drug abemaciclib and another widely used treatment slowed disease progression.
Nektar Therapeutics said its experimental opioid succeeded in a key late-stage study.
Shares of Cerulean Inc. plunged more than 61 percent this morning after the company announced it was being acquired by privately held Dare Bioscience, and has sold off some of its assets to BlueLink Pharmaceuticals and Novartis.
CytomX Therapeutics and Bristol-Myers Squibb are strengthening their relationship with the expansion of a 2014 collaboration agreement. The companies announced a plan to include up to eight additional targets, six in oncology and two in non-oncology areas, using CytomX’s proprietary Probody platform.
China is considering taking measures that will shorten the time to market for approved imported drugs in an effort to ease a shortage of such medicines, according to the China Food and Drug Administration (CFDA).
A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released from a so-called real world study sponsored by AstraZeneca.
Amgen Inc,’s Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clinical benefit beyond its ability to slash “bad” LDL cholesterol levels, data from a huge study known as Fourier showed on Friday.
Medtronic Plc’s non-invasive transcatheter aortic valve replacement (TAVR) system proved as safe as traditional surgery in intermediate-risk patients in a two-year study presented on Friday, paving the way for its use in a wider patient population.
India’s small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries.
Britain’s Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million.
In what feels a bit like a self-fulfilling prophecy, two analyst firms downgraded Biogen, causing the stock to drop.
Shares of Threshold Pharmaceuticals shot up more than 43 percent this morning after the company announced it was merging with Austin, Texas-based Molecular Templates Inc. and receiving an infusion of millions of dollars in financing.
The U.S. Food and Drug Administration gave AstraZeneca’s New Drug Application for ZS-9 (sodium zirconium cyclosiliate) a Complete Response Letter (CRL) — again. The drug was being developed for hyperkalemia by ZS Pharma, a wholly owned subsidiary of AstraZeneca.
Get thesis – completely unique job It takes much time to check out the certain matter and find out the needful results. Study paper requirements plenty of expertise to make a good one. This write is creating within the last season of examine and yes it demonstrates all your expertise and abilities.
PTC Therapeutics Inc. said on Thursday it would buy Marathon Pharmaceuticals LLC’s recently approved Duchenne muscular dystrophy drug, Emflaza, and promised to re-examine the hefty U.S. price tag on the treatment.
★Edu★ Your Optimal Success Guide For Research Paper Writing The land of the rising sun has given rise to so many technology related developments that it is really next to impossible to keep pace with. The rates charged should be reasonable in that they reflect the quality of papers.
Israel’s MedyMatch Technology said on Thursday IBM Watson Health would integrate MedyMatch’s technology into its offerings to imaging experts in hospitals to help doctors identify intracranial bleeding from head trauma and stroke.
Federal spending on health and human services takes a major blow under the first federal spending plan proposed by President Donald Trump.
The European Commission approved a label extension for three new indications for Shire’s Cinryze, broadening its use to children with hereditary angioedema.